Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils
Ying Fan, Andrew J.M. Howden, Adil R. Sarhan, et al.
Biochemical Journal (2017) Vol. 475, Iss. 1, pp. 23-44
Open Access | Times Cited: 158

Showing 1-25 of 158 citing articles:

Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Ahmad Elkouzi, Vinata Vedam‐Mai, Robert S. Eisinger, et al.
Nature Reviews Neurology (2019) Vol. 15, Iss. 4, pp. 204-223
Open Access | Times Cited: 252
The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human
Rafeeq Mir, Francesca Tonelli, Paweł Lis, et al.
Biochemical Journal (2018) Vol. 475, Iss. 11, pp. 1861-1883
Open Access | Times Cited: 193
LRRK2 links genetic and sporadic Parkinson's disease
Jillian H. Kluss, Adamantios Mamais, Mark Cookson
Biochemical Society Transactions (2019) Vol. 47, Iss. 2, pp. 651-661
Open Access | Times Cited: 187
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease
Danna Jennings, Sarah Huntwork‐Rodriguez, Anastasia G. Henry, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 648
Closed Access | Times Cited: 161
LRRK2 and idiopathic Parkinson’s disease
Emily M. Rocha, Matthew T. Keeney, Roberto Di Maio, et al.
Trends in Neurosciences (2022) Vol. 45, Iss. 3, pp. 224-236
Open Access | Times Cited: 105
A blood-based marker of mitochondrial DNA damage in Parkinson’s disease
Rui Qi, Esther Sammler, Claudia P. González-Hunt, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 711
Open Access | Times Cited: 43
Leucine-Rich Repeat Kinases
Dario R. Alessi, Suzanne R. Pfeffer
Annual Review of Biochemistry (2024) Vol. 93, Iss. 1, pp. 261-287
Closed Access | Times Cited: 17
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
S. Pablo Sardi, Jesse M. Cedarbaum, Patrik Brundin
Movement Disorders (2018) Vol. 33, Iss. 5, pp. 684-696
Open Access | Times Cited: 156
Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase
Paweł Lis, Sophie Burel, Martin Steger, et al.
Biochemical Journal (2017) Vol. 475, Iss. 1, pp. 1-22
Open Access | Times Cited: 143
LRRK2 regulation of immune-pathways and inflammatory disease
Rebecca L. Wallings, Malú G. Tansey
Biochemical Society Transactions (2019) Vol. 47, Iss. 6, pp. 1581-1595
Open Access | Times Cited: 125
Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease
Matthew Taylor, Dario R. Alessi
Current Opinion in Cell Biology (2020) Vol. 63, pp. 102-113
Open Access | Times Cited: 116
PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins
Kerryn Berndsen, Paweł Lis, Wondwossen M Yeshaw, et al.
eLife (2019) Vol. 8
Open Access | Times Cited: 114
Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation
Elizabeth M. Kline, Madelyn C. Houser, Mary K. Herrick, et al.
Movement Disorders (2020) Vol. 36, Iss. 1, pp. 25-36
Open Access | Times Cited: 95
LRRK2‐mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients
Farzaneh Atashrazm, Deborah Hammond, Gayathri Perera, et al.
Movement Disorders (2018) Vol. 34, Iss. 3, pp. 406-415
Closed Access | Times Cited: 94
RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase–mediated centrosomal cohesion and ciliogenesis deficits
Antonio Jesús Lara Ordóñez, Belén Fernández, Elena Fdez, et al.
Human Molecular Genetics (2019) Vol. 28, Iss. 21, pp. 3552-3568
Open Access | Times Cited: 88
Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner
Bojan Shutinoski, Mansoureh Hakimi, Irene E. Harmsen, et al.
Science Translational Medicine (2019) Vol. 11, Iss. 511
Closed Access | Times Cited: 83
LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages
Heyne Lee, Rowan Flynn, Ishta Sharma, et al.
Stem Cell Reports (2020) Vol. 14, Iss. 5, pp. 940-955
Open Access | Times Cited: 76
Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease?
Mary K. Herrick, Malú G. Tansey
npj Parkinson s Disease (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 69
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain
Enquan Xu, Ravindra Boddu, Hisham Abdelmotilib, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 48
Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson’s disease
Ludovica Iovino, Veronica Giusti, Francesca Pischedda, et al.
Acta Neuropathologica (2022) Vol. 144, Iss. 1, pp. 81-106
Open Access | Times Cited: 39
Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2
Hanwen Zhu, Francesca Tonelli, Martin Turk, et al.
Science (2023) Vol. 382, Iss. 6677, pp. 1404-1411
Open Access | Times Cited: 39
The systemic immune response in Parkinson’s disease: focus on the peripheral immune component
Johanne Lauritsen, Marina Romero‐Ramos
Trends in Neurosciences (2023) Vol. 46, Iss. 10, pp. 863-878
Open Access | Times Cited: 29
Rab12 is a regulator of LRRK2 and its activation by damaged lysosomes
Xiang Wang, Vitaliy V. Bondar, Oliver B. Davis, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 22
A potential patient stratification biomarker for Parkinson´s disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells
Yahaira Naaldijk, Belén Fernández, Rachel Fasiczka, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
Nicholas Pena, Tara Richbourg, Claudia P. González-Hunt, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top